FEED ENvue Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · OTC · SEC CIK 1326706 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-17.7%
TTM net income YoY-154.6%
TTM EPS YoY72.9%
Revenue 3-yr CAGR44.2%
Net income 3-yr CAGR—
Margins
Gross margin-26.1%
Operating margin-1,362.7%
Net margin-1,093.6%
FCF margin-609.8%
EBITDA margin-1,313.3%
Returns
ROE-59.1%
ROA-46.9%
ROIC (approx.)-62.7%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets19.9%
Debt / equity0.00x
Current ratio0.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-20.9%
Payout ratio—
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.55M | $2.56M |
| Cost of revenue | $2.40M | $1.05M |
| Gross profit | $153,000 | $1.51M |
| R&D expense | $1.76M | $909,000 |
| SG&A expense | $7.63M | $3.46M |
| Operating income | -$22.89M | -$3.58M |
| Interest expense | — | $135,000 |
| Pretax income | -$18.49M | -$3.69M |
| Income tax | -$307,000 | $19,000 |
| Net income | -$18.18M | -$3.71M |
| EBITDA | -$21.99M | -$3.58M |
| EPS (basic) | -26.69 | -137.30 |
| EPS (diluted) | -26.69 | -137.30 |
| Weighted avg. shares (diluted) | 628,534 | 26,985 |
| Balance sheet | ||
| Cash & equivalents | $4.22M | $752,000 |
| Receivables | $289,000 | $98,000 |
| Inventory | $2.34M | $2.19M |
| Current assets | $7.27M | $3.33M |
| PP&E, net | $119,000 | $9,000 |
| Goodwill | $29.08M | — |
| Intangibles | $4.38M | — |
| Total assets | $41.12M | $3.63M |
| Current liabilities | $6.66M | $2.72M |
| Total liabilities | $7.63M | $3.00M |
| Shareholders' equity | $33.50M | $627,000 |
| Shares outstanding | 1.10M | 37,894 |
| Cash flow statement | ||
| Operating cash flow | -$9.37M | -$2.52M |
| Capital expenditure | $60,000 | $3,000 |
| Free cash flow | -$9.43M | -$2.52M |
| Investing cash flow | $88,000 | -$3,000 |
| Financing cash flow | $12.79M | $1,000 |
| Depreciation & amortization | $897,000 | $1,000 |
| Stock-based compensation | — | $356,000 |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.